Revista Biom�dica Revisada Por Pares

Abrir sesi�n | Reg�strese | Contacto | English |

Res�menes Epistemonikos

Medwave 2016;16(Suppl5):e6793 doi: 10.5867/medwave.2016.6793

�Tienen alg�n rol los cannabinoides en el s�ndrome de Tourette?

Do cannabinoids have a role to play in Tourette�s syndrome?

Karen Garc�a, Gabriel Rada

Referencias | Descargar PDF | Imprimir | A(+) A(-) | Lectura f�cil

Abstract

It has been suggested that the use of cannabinoids might play a role in the treatment of Tourette�s syndrome, but there is no consensus. Searching in Epistemonikos database, which is maintained by screening multiple databases, we identified seven systematic reviews including two randomized trials addressing the question of this article. We extracted data, combined the evidence using meta-analysis and generated a summary of findings following the GRADE approach. We concluded it is not clear whether cannabinoids reduce tics in Tourette�s syndrome, and they are probably associated to frequent adverse effects.

Problem

Tourette's syndrome is a neuropsychiatric disorder characterized by the presence of involuntary movements (motor tics) and vocalizations (vocal tics). In this condition, there is a lack of inhibition of neuronal cortico-striatal-thalamic-cortical circuits. Many drugs have been tried in order to reduce tics, with responses not entirely satisfactory. In the search for new therapies, the use of cannabinoids has been put forward, but there is no clear consensus about their clinical role.

Methods

We used Epistemonikos database, which is maintained by screening multiple databases, to identify systematic reviews and their included primary studies. With this information, we generated a structured summary using a pre-established format, which includes key messages, a summary of the body of evidence (presented as an evidence matrix in Epistemonikos), meta-analysis of the total of studies, a summary of findings table following the GRADE approach and a table of other considerations for decision-making.

Key messages

It is not clear whether cannabinoids reduce tics in Tourette’s syndrome, and they are probably associated to frequent adverse effects.

About the body of evidence for this question

What is the evidence. See evidence matrix in Epistemonikos later	We found seven systematic reviews [1],[2],[3],[4],[5],[6],[7] including two randomized controlled trials reported in four references [8],[9],[10],[11].
What types of patients were included	Both trials enrolled men and women diagnosed with Tourette’s syndrome based on DSM III criteria.
What types of interventions were included	Both trials evaluated the use of tetrahydrocannabinol capsules administered orally. In one trial, the dose was 5 mg, 7.5 mg or 10 mg once [9], and in the other trial, the dose was not specified [8]. Both trials compared against placebo.
What types of outcomes were measured	The systematic reviews assessed the following outcomes: Improvement in severity of tics measured by different scales (TSSL, STSSS, YGTSS, TSGS, TS-CGI*). Adverse effects followed up to 42 days after the end of trial. Other outcomes measured were obsessive-compulsive disorder, foreboding anxiety, cognitive function alteration, attention deficit hyperactive disorder.

* TSSL = Tourette's syndrome symptoms list; STSSS = Shapiro Tourette syndrome severity scale; YGTSS = Yale Global Tic Severity Scale; TSGS = Tourette's syndrome global scale; TSC-GI = Tourette's syndrome clinical global impression scale

Both trials evaluated the use of tetrahydrocannabinol capsules administered orally. In one trial, the dose was 5 mg, 7.5 mg or 10 mg once [9], and in the other trials, the dose was not specified [8].

Both trials compared against placebo.

Summary of findings

The Information on the effects of cannabinoids for Tourette’s syndrome is based on two randomized trials including 28 patients in total [8], [9]. Both trials measured the severity of tics, using different scales. The summary of findings is as follows:

Key messages

It is not clear whether cannabinoids reduce tics in Tourette’s syndrome because the certainty of the evidence is very low.
Cannabinoids are probably associated to frequent adverse effects. The certainty of the evidence is moderate.

Other considerations for decision-making

To whom this evidence does and does not apply

The evidence presented in this summary applies to adults with Tourette’s syndrome diagnosed according to DSM III criteria.
While there are no trials in children, in the absence of evidence, it is reasonable to extrapolate the findings of this summary.

About the outcomes included in this summary

The outcomes severity of tics and adverse effects were considered critical for decision making by the authors of this summary, and this is in line with those used by systematic reviews and guidelines.

Balance between benefits and risks, and certainty of the evidence

The evidence on the benefits has very low certainty, and adverse effects are common. So, the benefit/risk ratio is not favorable.

What would patients and their doctors think about this intervention

Based on the existing evidence most patients and doctors should lean against the use of this intervention.
Some patients putting more value on an uncertain benefit might decide to use it, especially taking into account preconceived ideas or non-conclusive recommendations in some guidelines.

Resource considerations

Commercial formulations of cannabinoids are generally expensive. Since there is no certainty about benefits, it is not possible to estimate a cost/benefit balance.

Differences between this summary and other sources

The systematic reviews differ slightly between them. Some argue it is a promising therapy [2],[5],[6], while others emphasize the lack of evidence [1],[3],[7].
The conclusions of this summary partially disagree with some of the major guidelines, which make a weak recommendation in adults (not in children, because there are no studies), or take no clear position on the issue [12],[13].

Could this evidence change in the future?

The probability that future evidence changes the conclusion of this summary regarding the benefits of cannabinoids in Tourette’s syndrome is high, because of the existing uncertainty. Regarding adverse effects, the probability is low.
There are no ongoing trials on this topic according to the International Clinical Trials Registry Platform of the World Health Organization.

How we conducted this summary

Using automated and collaborative means, we compiled all the relevant evidence for the question of interest and we present it as a matrix of evidence.

Follow the link to access the interactive version: Cannabinoids for Tourette's syndrome

Notes

The upper portion of the matrix of evidence will display a warning of “new evidence” if new systematic reviews are published after the publication of this summary. Even though the project considers the periodical update of these summaries, users are invited to comment in Medwave or to contact the authors through email if they find new evidence and the summary should be updated earlier. After creating an account in Epistemonikos, users will be able to save the matrixes and to receive automated notifications any time new evidence potentially relevant for the question appears.

The details about the methods used to produce these summaries are described here http://dx.doi.org/10.5867/medwave.2014.06.5997.

Epistemonikos foundation is a non-for-profit organization aiming to bring information closer to health decision-makers with technology. Its main development is Epistemonikos database (www.epistemonikos.org).

These summaries follow a rigorous process of internal peer review.

Conflicts of interest
The authors do not have relevant interests to declare.

Licencia Creative Commons

Esta obra de Medwave est� bajo una licencia Creative Commons Atribuci�n-NoComercial 3.0 Unported. Esta licencia permite el uso, distribuci�n y reproducci�n del art�culo en cualquier medio, siempre y cuando se otorgue el cr�dito correspondiente al autor del art�culo y al medio en que se publica, en este caso, Medwave.

Edici�n Julio 2022

Estudios originales

Caracterizaci�n cl�nica, psicol�gica y sociofamiliar de la conducta suicida en adolescentes chilenos: an�lisis de correspondencias m�ltiples

Asociaci�n de biomarcadores y severidad de COVID-19: estudio transversal

Sistematizaci�n de iniciativas en salud sexual y reproductiva seg�n criterios de buenas pr�cticas en repuesta a la pandemia COVID-19 en la atenci�n primaria en Chile